Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 374.2 INR 0.53% Market Closed
Market Cap: 187B INR
Have any thoughts about
Eris Lifesciences Ltd?
Write Note

Intrinsic Value

The intrinsic value of one ERIS stock under the Base Case scenario is 1 082.77 INR. Compared to the current market price of 1 374.2 INR, Eris Lifesciences Ltd is Overvalued by 21%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ERIS Intrinsic Value
1 082.77 INR
Overvaluation 21%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Eris Lifesciences Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ERIS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ERIS?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Eris Lifesciences Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Eris Lifesciences Ltd

Provide an overview of the primary business activities
of Eris Lifesciences Ltd.

What unique competitive advantages
does Eris Lifesciences Ltd hold over its rivals?

What risks and challenges
does Eris Lifesciences Ltd face in the near future?

Has there been any significant insider trading activity
in Eris Lifesciences Ltd recently?

Summarize the latest earnings call
of Eris Lifesciences Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Eris Lifesciences Ltd.

Provide P/S
for Eris Lifesciences Ltd.

Provide P/E
for Eris Lifesciences Ltd.

Provide P/OCF
for Eris Lifesciences Ltd.

Provide P/FCFE
for Eris Lifesciences Ltd.

Provide P/B
for Eris Lifesciences Ltd.

Provide EV/S
for Eris Lifesciences Ltd.

Provide EV/GP
for Eris Lifesciences Ltd.

Provide EV/EBITDA
for Eris Lifesciences Ltd.

Provide EV/EBIT
for Eris Lifesciences Ltd.

Provide EV/OCF
for Eris Lifesciences Ltd.

Provide EV/FCFF
for Eris Lifesciences Ltd.

Provide EV/IC
for Eris Lifesciences Ltd.

Show me price targets
for Eris Lifesciences Ltd made by professional analysts.

What are the Revenue projections
for Eris Lifesciences Ltd?

How accurate were the past Revenue estimates
for Eris Lifesciences Ltd?

What are the Net Income projections
for Eris Lifesciences Ltd?

How accurate were the past Net Income estimates
for Eris Lifesciences Ltd?

What are the EPS projections
for Eris Lifesciences Ltd?

How accurate were the past EPS estimates
for Eris Lifesciences Ltd?

What are the EBIT projections
for Eris Lifesciences Ltd?

How accurate were the past EBIT estimates
for Eris Lifesciences Ltd?

Compare the revenue forecasts
for Eris Lifesciences Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Eris Lifesciences Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Eris Lifesciences Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Eris Lifesciences Ltd compared to its peers.

Compare the P/E ratios
of Eris Lifesciences Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Eris Lifesciences Ltd with its peers.

Analyze the financial leverage
of Eris Lifesciences Ltd compared to its main competitors.

Show all profitability ratios
for Eris Lifesciences Ltd.

Provide ROE
for Eris Lifesciences Ltd.

Provide ROA
for Eris Lifesciences Ltd.

Provide ROIC
for Eris Lifesciences Ltd.

Provide ROCE
for Eris Lifesciences Ltd.

Provide Gross Margin
for Eris Lifesciences Ltd.

Provide Operating Margin
for Eris Lifesciences Ltd.

Provide Net Margin
for Eris Lifesciences Ltd.

Provide FCF Margin
for Eris Lifesciences Ltd.

Show all solvency ratios
for Eris Lifesciences Ltd.

Provide D/E Ratio
for Eris Lifesciences Ltd.

Provide D/A Ratio
for Eris Lifesciences Ltd.

Provide Interest Coverage Ratio
for Eris Lifesciences Ltd.

Provide Altman Z-Score Ratio
for Eris Lifesciences Ltd.

Provide Quick Ratio
for Eris Lifesciences Ltd.

Provide Current Ratio
for Eris Lifesciences Ltd.

Provide Cash Ratio
for Eris Lifesciences Ltd.

What is the historical Revenue growth
over the last 5 years for Eris Lifesciences Ltd?

What is the historical Net Income growth
over the last 5 years for Eris Lifesciences Ltd?

What is the current Free Cash Flow
of Eris Lifesciences Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Eris Lifesciences Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Eris Lifesciences Ltd

Current Assets 23B
Cash & Short-Term Investments 964.7m
Receivables 4.3B
Other Current Assets 17.8B
Non-Current Assets 47.5B
Long-Term Investments 248.7m
PP&E 5.2B
Intangibles 38.2B
Other Non-Current Assets 3.7B
Current Liabilities 25.3B
Accounts Payable 2.7B
Other Current Liabilities 22.6B
Non-Current Liabilities 19.3B
Long-Term Debt 6.9B
Other Non-Current Liabilities 12.4B
Efficiency

Earnings Waterfall
Eris Lifesciences Ltd

Revenue
22.6B INR
Cost of Revenue
-4.8B INR
Gross Profit
17.8B INR
Operating Expenses
-12.4B INR
Operating Income
5.4B INR
Other Expenses
-1.6B INR
Net Income
3.8B INR

Free Cash Flow Analysis
Eris Lifesciences Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Eris Lifesciences reported a consolidated Q1 revenue of INR 720 crores, marking a 54% year-over-year increase, and an EBITDA of INR 250 crores, a 47% rise. The company successfully integrated Biocon acquisitions, achieving substantial synergies. The Biocon segment alone is expected to contribute 25% growth in FY '25. Eris' model now encompasses specialty and super specialty segments, including oncology and critical care. The guidance for the year includes a revenue target of over INR 3,000 crores and an EBITDA margin of 35%.

What is Earnings Call?
Fundamental Scores

ERIS Profitability Score
Profitability Due Diligence

Eris Lifesciences Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Positive Operating Income
Exceptional 3-Years Revenue Growth
63/100
Profitability
Score

Eris Lifesciences Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

ERIS Solvency Score
Solvency Due Diligence

Eris Lifesciences Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Low D/E
Average Altman Z-Score
Long-Term Solvency
Short-Term Solvency
48/100
Solvency
Score

Eris Lifesciences Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ERIS Price Targets Summary
Eris Lifesciences Ltd

Wall Street analysts forecast ERIS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ERIS is 1 543.77 INR with a low forecast of 1 242.3 INR and a high forecast of 1 764 INR.

Lowest
Price Target
1 242.3 INR
10% Downside
Average
Price Target
1 543.77 INR
12% Upside
Highest
Price Target
1 764 INR
28% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ERIS?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ERIS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ERIS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

186.9B INR

Dividend Yield

0%

Description

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

Contact

GUJARAT
Ahmedabad
8th Floor, Commerce House- IV,, Prahladnagar, 100 ft road
+917930451111
www.eris.co.in

IPO

2017-06-29

Employees

3 246

Officers

Chairman & MD
Mr. Amit Indubhushan Bakshi
Chief Financial Officer
Mr. Sachin Shah
Executive Director & COO
Mr. Krishnakumar Vaidyanathan
President of Sales & Marketing
Mr. Gagan Atreja
Executive Director
Mr. Inderjeet Singh Negi
Whole Time Director
Mr. Kaushal Kamlesh Shah
Show More
Senior Vice President
Mr. Deepak Kapoor
Compliance Officer & Company Secretary
Mr. Milind Talegaonkar
President Medical
Mr. Vijay S. Joshi
Vice President
Mr. Manish Kapoor
Show Less

See Also

Discover More
What is the Intrinsic Value of one ERIS stock?

The intrinsic value of one ERIS stock under the Base Case scenario is 1 082.77 INR.

Is ERIS stock undervalued or overvalued?

Compared to the current market price of 1 374.2 INR, Eris Lifesciences Ltd is Overvalued by 21%.

Back to Top